Previous close | 221.81 |
Open | 224.27 |
Bid | 202.00 x 900 |
Ask | 245.00 x 1100 |
Day's range | 225.63 - 233.91 |
52-week range | 161.65 - 275.00 |
Volume | |
Avg. volume | 512,909 |
Market cap | 12.026B |
Beta (5Y monthly) | 1.38 |
PE ratio (TTM) | 27.40 |
EPS (TTM) | 8.52 |
Earnings date | 07 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 254.80 |
Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
WILMINGTON, Mass. & SAN FRANCISCO, July 24, 2024--Charles River and Autobahn Labs announce collaborative program; Charles River CSO Justin Bryans joins Autobahn's Board of Directors
WILMINGTON, Mass., July 16, 2024--Charles River Laboratories schedules second-quarter 2024 earnings release and conference call for Wednesday, August 7th.